 |
|
|
|
|
|
|
|
 |
|
|
UROsphere is a biopharmaceutical company founded in 2004 by 2 senior scientists having cumulatively more than 25 years experience in R&D in the pharmaceutical industry.
Our vision
“Since the creation of UROsphere, we have chosen to develop a preclinical CRO that would be an expertise center for genitourinary pathologies.
To meet our clients’ needs we have chosen to develop both scientific expertise and a flexible, reactive and personalized customer service.
UROsphere’s team is highly experienced and well recognized for it’s scientific expertise.
We value a privileged scientific and human relationship with our clients starting from consulting, ad-hoc protocols as well as high quality of studies and reports.
Being a niche CRO means for us being the best in all we do.”
Our facilities
UROsphere’s offices and laboratories (a dedicated space of 400 m2) are located in Toulouse, France. The company benefits of the scientific and business potential of Midi-Pyrénées region.
Midi-Pyrénées region is an emerging Biopole with centers of excellence in Health and Medicine, Food and Industrial Agro-Biotechnologies. The presence of international groups and an impressive public and private R&D network in Life Sciences allows significant development potential in Bio&Techs. The region has also developped a strong network to support business creation, development and innovation.
Your advantages
-
"State of the art" experimental approaches. UROsphere constantly improves its models in relation to the latest significant publications.
-
An evaluation of your drug candidates in human tissues before the clinic: building evidence that your drug candidate will work in humans.
-
In vitro and in vivo multispecies experimental models.
-
A large range of pre-clinical and clinical competences concentrated in the same structure.
-
A guarantee for the quality of experimental studies: Regular auditor, Veterinary services agreements, editing of study reports according to ICH directives…
-
A team of experts optimizing your time in pre-clinical development.
|
|
|
|
